I have to be honest, I'm happy as a shareholder of the company but I'm not quite sure what it is justifying the move higher at the moment besides maybe the fact that it isn't a name that's covered all that much. weren't ADCETRIS sales flat recently? that and I don't think there's major data coming out for any of its next important drugs until next year, correct? it starts to make me a little cautious
I also sold 100% on Friday. I can't remember not owning any SGEN. I also lighten up on everything. It's more a sell on the market than SGEN. I also feel like I will regret selling here but I can't see any near term fundamentals which justify the current price.
Good luck to you all.
I have to say, I am astonished. Happy, but astonished. It does feel like it's getting way ahead of itself, but...hey...we've all been on the other side of that phenomenon, so I'm just sitting back and enjoying this.
The addition of the duration indication alone has the potential to dramatically increase sales. Before Adcetris these patients literally had no hope. They, because of toxicity, had reached their life time limit of chemo. Since Adcetris is so well tolerated it's full potential and duration has not been established. Patients that once faced certain death can live perhaps many years and what was once a deadly disease for many has become a chronic, treatable disease.
The key word for investors is chronic....many treatments over a long period of time.. multiplied by the many indications under trial.
But yes maybe we are a little ahead of ourselves here. If the market ever takes a breather this will most likely follow it down and give us another buying opportunity.
volume is decent. mutuals must be accumulating with many people putting their cash back into the market. they are investing in the future of adcetris and ADCs, not the present. Aside from Takeda, Roche knows how those ADCs are doing and could buyout SGEN rather than pay for future royalties, at the same time own the ADC IPs for their use alone. however, just one downgrade again based on current revenues and we're back to 30 or less.